Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials
Diabetes, Obesity and Metabolism · 2026-02 · 28 (2) · 1105-1115
DOI: 10.1111/dom.70289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.11.2025. Verfasst von João Pedro Ferreira und 10 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Boehringer Ingelheim, Eli Lilly.
Abstract (Originalsprache)
Background
Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors ( SGLT2i ) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease ( CKD ). Patients with low‐ or without albuminuria have been underrepresented in randomised clinical trials ( RCTs ), and the effects of SGLT2i on cardiovascular and kidney outcomes across the full range of albuminuria require further investigation.
Aims
To study the effects of SGLT2i on kidney and cardiovascular outcomes across albuminuria levels in populations with different cardiovascular–kidney–metabolic ( CKM ) risk.
Methods
Individual‐patient data pooled analysis of RCTs across the CKM spectrum. Outcomes were studied across urinary albumin‐to‐creatinine ratio ( UACR ) both as categorical and continuous variables using survival and mixed effects models.
Results
A total of 26 750 patients were included. The median (pct 25‐75 ) baseline UACR was 28 (8–240) mg/g: 13 669 (51.1%) had UACR 300 mg/g. Compared to patients with lower UACR , those with higher UACR were younger, with a more frequent history of hypertension, diabetes, and obesity, and lower eGFR . UACR was linearly associated with kidney and cardiovascular outcomes as well as mortality. Compared to placebo, SGLT2i reduced the risk of kidney events, HF hospitalisations, atherothrombotic events, cardiovascular and all‐cause mortality across the full UACR spectrum (Pinteraction >0.1 for all outcomes). Compared to placebo, SGLT2i reduced albuminuria levels by 13%, on average: gMratio 0.87, 95% CI 0.85–0.88, p < 0.001.
Conclusions
Higher albuminuria was associated with an increased risk of cardiovascular and kidney outcomes. SGLT2i improved cardiovascular and kidney outcomes across the full range of albuminuria, including normo‐albuminuria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
- Université de Lorraine, INSERM, Centre d'Investigations Cliniques, CHRU de Nancy, Inserm and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.
- Serviço de Medicina Interna, Unidade Local de Saúde São João, Porto, Portugal.
- Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
- Baylor Scott and White Research Institute, Dallas, TX and University of Mississippi, Jackson, Mississippi, USA.
- National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
ORCID-Profile: João Pedro Ferreira, Javed Butler, Abhinav Sharma, Luís Mendonça
Förderung
- CIHR
- Boehringer Ingelheim
- Eli Lilly
- Janssen Research and Development
- Canadian Institutes of Health Research
Zitieren
APA
Ferreira, J. P., Marques, P., Anker, S. D., Butler, J., Filippatos, G., Sharma, A., Vasques-Nóvoa, F., Mendonça, L., Neves, J. S., Packer, M., & Zannad, F. (2026). Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials. Diabetes, Obesity and Metabolism, 28(2), 1105-1115. https://doi.org/10.1111/dom.70289
Vancouver
Ferreira JP, Marques P, Anker SD, Butler J, Filippatos G, Sharma A, et al. Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials. Diabetes, Obesity and Metabolism. 2026;28(2):1105-1115. doi:10.1111/dom.70289
BibTeX
@article{Ferreira2026,
author = {Ferreira, João Pedro and Marques, Pedro and Anker, Stefan D and Butler, Javed and Filippatos, Gerasimos and Sharma, Abhinav and Vasques-Nóvoa, Francisco and Mendonça, Luís and Neves, João Sérgio and Packer, Milton and Zannad, Faiez},
title = {Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {2},
pages = {1105--1115},
doi = {10.1111/dom.70289}
}
EUVIMED